Key Highlights
- Loss per ordinary share was USD 0.26 against an estimate of a USD 0.27 loss.
- License and collaboration revenues were USD 736 thousand, compared with USD 16 thousand.
- Net loss was USD 16.15 million, compared with USD 17.20 million.
- Cash was USD 16.50 million and short-term investments were USD 2.99 million.
Connect Biopharma (NASDAQ:CNTB) reported license and collaboration revenues of USD 736 thousand for the third quarter of 2026, compared with USD 16 thousand in the prior-year quarter. Basic and diluted net loss per ordinary share was USD 0.26, compared with USD 0.31, against an estimate of a USD 0.27 loss.
Net loss was USD 16.15 million, compared with USD 17.20 million. The company, headquartered in San Diego, California, describes itself as a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease.
Third Quarter Results
Research and development expense was USD 12.79 million, compared with USD 11.11 million, and general and administrative expense was USD 4.26 million, compared with USD 6.58 million. Total operating expenses were USD 17.05 million, compared with USD 17.69 million, and the loss from operations was USD 16.31 million, compared with USD 17.68 million.
Interest income was USD 185 thousand, compared with USD 545 thousand, and total other income, net, was USD 182 thousand, compared with USD 538 thousand. Income tax expense was USD 20 thousand. Weighted average ordinary shares outstanding were 62,974 thousand, compared with 55,716 thousand.
Nine-Month Results
For the nine months ended September 30, 2026, license and collaboration revenues were USD 3.67 million, compared with USD 64 thousand. Research and Development expense was USD 44.09 million, compared with USD 26.52 million, and general and administrative expense was USD 13.10 million, compared with USD 16.10 million.
The loss from operations for the nine months was USD 53.52 million, compared with USD 42.55 million, and the net loss was USD 52.83 million, compared with USD 40.37 million. Basic and diluted net loss per ordinary share was USD 0.87, compared with USD 0.73. The comprehensive loss was USD 52.52 million, compared with USD 39.98 million.
Balance Sheet and Going Concern Disclosure
Cash and cash equivalents were USD 16.50 million at September 30, 2026, compared with USD 38.35 million at December 31, 2025, and short-term investments were USD 2.99 million, compared with USD 6.00 million. Total Assets were USD 27.77 million, compared with USD 56.08 million, and total liabilities were USD 15.72 million, compared with USD 14.10 million. Total current liabilities were USD 15.50 million.
During the nine months, the company issued 6,130 thousand ordinary shares in a private placement, with net proceeds of USD 18.58 million after issuance costs. The filing states that cash, cash equivalents and short-term investments are insufficient to meet the company's anticipated cash requirements for at least one year from the filing date, and discloses substantial doubt about the company's ability to continue as a going concern.
Connect Biopharma Q3 2026 Earnings: Key Takeaways
Connect Biopharma reported third quarter 2026 license and collaboration revenues of USD 736 thousand and a net loss of USD 16.15 million. Cash and cash equivalents were USD 16.50 million at September 30, 2026.





_11_18_2026_14_25_43_237129.jpg)
Please wait processing your request...